3 terminated, 1 completed. 1 Early Phase 1, 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 4 | 1 | Terminated 1 |
Follow FoxHollow Technologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease NightHawk - Peripheral Vascular Diseases | Phase 2 | Terminated | FoxHollow Technologies | 100 | 2007-08-01 | 2008-01-18 |
| A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED) MK-0736, Comparator: placebo (unspecified) - Peripheral Vascular Diseases | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 14 | 2007-03-31 | 2018-08-17 |
| Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia Bypass, Silverhawk Plaque Excision - Peripheral Vascular Diseases | Phase 4 | Terminated | FoxHollow Technologies | 2006-10-01 | 2008-08-20 | |
| Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease. Simvastatin, Losartan, Pioglitazone - Peripheral Arterial Disease | Early Phase 1 | Completed | Medtronic Endovascular | 164 | 2005-12-01 | 2021-05-14 |
Peripheral Vascular Diseases (3) · Chronic Limb-Threatening Ischemia (2) · Peripheral Arterial Disease (2)
Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent (1) · Losartan (1) · Pioglitazone (1) · Simvastatin (1)
United States (2)
David Kandzari, MD (1) · James F. McKinsey, M.D. (1)